Navigation Links
Shire plc: Change to Director's Details
Date:2/5/2009

PHILADELPHIA and DUBLIN, February 5 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Mr Matthew Emmens, non-executive Chairman of Shire, has been appointed President of Vertex Pharmaceuticals Incorporated with immediate effect and that Mr Emmens will in addition become Chairman and Chief Executive Officer of Vertex in May 2009 when the current Chief Executive Officer retires.

    This announcement is made pursuant to Listing Rule 9.6.14R.

    Tony Guthrie
    Deputy Company Secretary


    Notes to editors
    Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

    For further information please contact:

    Investor Relations
    Clea Rosenfeld (Rest of the World)
    +44-1256-894-160

    Eric Rojas (North America)
    +1-617-551-9715

    Media
    Matthew Cabrey (Specialty Pharma)
    +1-484-595-8248

    Jessica Cotrone (HGT)
    +1-617-613-4640


'/>"/>
SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
2. Shires New Product Portfolio Delivers Strong Quarterly Performance
3. Change of Name to Shire plc
4. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
5. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
6. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
7. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
8. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
9. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
10. Application for Listing of Shire Limited Ordinary Shares
11. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
(Date:2/3/2016)... 3, 2016  Discovery Laboratories, Inc. (NASDAQ: ... aerosolized KL4 surfactant therapies for respiratory diseases, today ... an inducement award as a component of employment ... appointed President and Chief Executive Officer.  The award ... February 1, 2016 and granted as an inducement ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
(Date:2/3/2016)... 2016  Today, Symphony Technology Group (STG) announced the ... leading provider of primary research and analytics-based insight for ... , a global information and technology services company serving ... will be integrated into IMS Health to form a ... capabilities. ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
Breaking Biology News(10 mins):